

# Consolidated Financial Results for Fiscal 2015

(Reference Data of Financial Statements for the 3Q of Fiscal 2015)

February 5, 2016

**KAKEN PHARMACEUTICAL CO., LTD.**

Corporate Communications

Tel: +81-(0)3-5977-5002

Fax: +81-(0)3-5977-5131

Email: [koho@kaken.co.jp](mailto:koho@kaken.co.jp)

ACRUX DDS PTY LTD. et al.

EXHIBIT 1648

IPR Petition for

1. Summary of Consolidated Financial Statements for the Third Quarter of Fiscal 2015

( Figures less than one million yen have been omitted)

	FY2014 3rd Q	FY2014	FY2015 3rd Q	Y o Y increase (decrease)		FY2015 Forecasts	Y o Y increase (decrease)	
				Yen	%		Yen	%
Net sales	71,155	93,889	85,431	14,275	120.1%	107,900	14,011	114.9%
Operating income	16,611	20,631	29,689	13,077	178.7%	32,200	11,569	156.1%
Ratio of net sales	23.3%	22.0%	34.8%			29.8%		
Ordinary income	16,474	20,394	29,919	13,445	181.6%	32,400	12,006	158.9%
Ratio of net sales	23.2%	21.7%	35.0%			30.0%		
Net income	9,605	12,122	20,134	10,529	209.6%	19,200	7,078	158.4%
Ratio of net sales	13.5%	12.9%	23.6%			17.8%		
Comprehensive income	11,650	16,607	20,711	9,061	177.8%			
R&D expenses	4,806	7,615	4,392	(413)	91.4%	8,300	685	109.0%

2. Breakdown of Sales by Main Pharmaceuticals and Medical Devices

( Figures less than one million yen have been omitted)

	FY2014 3rd Q	FY2014	FY2015 3rd Q	%	FY2015 Forecasts	%
Anti-osteoarthritis Artz	23,922	30,259	24,250	101.4%	30,600	101.1%
Anti-nail fungus Clenafin	4,039	6,857	15,385	380.9%	18,500	269.8%
Post-operative anti-adhesive Seprafilm	8,425	10,791	8,711	103.4%	11,200	103.8%
Anti-hyperlipidemia Lipidil	3,361	4,373	3,495	104.0%	4,600	105.2%
Wound healing agent Fiblast Spray	2,623	3,511	2,723	103.8%	3,600	102.5%
Generic products	9,479	12,380	10,237	108.0%	13,300	107.4%
Sales of Jublia*	2,386	3,318	4,986	209.0%	5,600	168.8%

(\* including sales of API and finished product, royalty revenue and milestone revenue)

KAKEN PHARMACEUTICAL CO., LTD.